Lisraya, an oral tyrosine kinase 2/Janus kinase inhibitor, achieved its primary endpoint in two phase 3 clinical trials investigating it for the treatment of noninfectious uveitis, according to a press release.
“It has been nearly a decade since we last had an FDA-approved systemic therapy (adalimumab) for uveitis and ocular inflammatory diseases,” Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, principal investigator in the phase 3 CLARITY trials, told Healio. “The field is in dire need for an effective, non-invasive therapy (non-injection in the skin or the muscle or inside the eye, just oral